Vanguard Group’s Cellectar Biosciences CLRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $263K | Buy |
89,120
+23,949
| +37% | +$88.4K | ﹤0.01% | 4064 |
|
|
2025
Q3 | $365K | Buy |
65,171
+8,830
| +16% | +$43.7K | ﹤0.01% | 4020 |
|
|
2025
Q2 | $401K | Sell |
56,341
-1,054
| -2% | -$9.22K | ﹤0.01% | 3972 |
|
|
2025
Q1 | $542K | Sell |
57,395
-172
| -0.3% | -$1.56K | ﹤0.01% | 3866 |
|
|
2024
Q4 | $516K | Buy |
57,567
+1
| +0% | +$46 | ﹤0.01% | 3945 |
|
|
2024
Q3 | $3.7M | Buy |
57,566
+5,433
| +10% | +$358K | ﹤0.01% | 3381 |
|
|
2024
Q2 | $3.91M | Buy |
52,133
+12,430
| +31% | +$1.19M | ﹤0.01% | 3356 |
|
|
2024
Q1 | $4.74M | Buy |
39,703
+23,607
| +147% | +$2.56M | ﹤0.01% | 3318 |
|
|
2023
Q4 | $1.34M | Buy |
16,096
+10,233
| +175% | +$762K | ﹤0.01% | 3735 |
|
|
2023
Q3 | $464K | Buy |
5,863
+131
| +2% | +$7.72K | ﹤0.01% | 4070 |
|
|
2023
Q2 | $335K | Sell |
5,732
-117
| -2% | -$5.63K | ﹤0.01% | 4217 |
|
|
2023
Q1 | $251K | Hold |
5,849
| – | – | ﹤0.01% | 4284 |
|
|
2022
Q4 | $300K | Buy |
5,849
+3
| +0.1% | +$180 | ﹤0.01% | 4223 |
|
|
2022
Q3 | $589K | Hold |
5,846
| – | – | ﹤0.01% | 4169 |
|
|
2022
Q2 | $708K | Hold |
5,846
| – | – | ﹤0.01% | 4193 |
|
|
2022
Q1 | $1.21M | Sell |
5,846
-692
| -11% | -$121K | ﹤0.01% | 4151 |
|
|
2021
Q4 | $1.3M | Sell |
6,538
-9
| -0.1% | -$2.17K | ﹤0.01% | 4184 |
|
|
2021
Q3 | $1.82M | Buy |
6,547
+298
| +5% | +$90.9K | ﹤0.01% | 4090 |
|
|
2021
Q2 | $2.23M | Buy |
6,249
+771
| +14% | +$334K | ﹤0.01% | 3941 |
|
|
2021
Q1 | $2.65M | Buy |
5,478
+433
| +9% | +$257K | ﹤0.01% | 3800 |
|
|
2020
Q4 | $3.15M | Buy |
5,045
+4,809
| +2,038% | +$2.21M | ﹤0.01% | 3543 |
|
|
2020
Q3 | $88K | Buy |
236
+180
| +321% | +$71.1K | ﹤0.01% | 4029 |
|
|
2020
Q2 | $21K | Hold |
56
| – | – | ﹤0.01% | 4060 |
|
|
2020
Q1 | $22K | Hold |
56
| – | – | ﹤0.01% | 4043 |
|
|
2019
Q4 | $38K | Hold |
56
| – | – | ﹤0.01% | 4059 |
|
|
2019
Q3 | $34K | Hold |
56
| – | – | ﹤0.01% | 4104 |
|
|
2019
Q2 | $37K | Hold |
56
| – | – | ﹤0.01% | 4129 |
|
|
2019
Q1 | $39K | Hold |
56
| – | – | ﹤0.01% | 4074 |
|
|
2018
Q4 | $26K | Hold |
56
| – | – | ﹤0.01% | 4108 |
|
|
2018
Q3 | $50K | Sell |
56
-26
| -32% | -$30.6K | ﹤0.01% | 4127 |
|
|
2018
Q2 | $153K | Buy |
82
+1
| +1% | +$3.07K | ﹤0.01% | 4008 |
|
|
2018
Q1 | $277K | Buy |
81
+2
| +3% | +$7.15K | ﹤0.01% | 3909 |
|
|
2017
Q4 | $325K | Buy |
79
+30
| +61% | +$134K | ﹤0.01% | 3841 |
|
|
2017
Q3 | $246K | Hold |
49
| – | – | ﹤0.01% | 3877 |
|
|
2017
Q2 | $240K | Buy |
49
+12
| +32% | +$65.8K | ﹤0.01% | 3871 |
|
|
2017
Q1 | $253K | Buy |
37
+14
| +61% | +$83.2K | ﹤0.01% | 3867 |
|
|
2016
Q4 | $85K | Buy |
23
+9
| +64% | +$48.8K | ﹤0.01% | 3988 |
|
|
2016
Q3 | $111K | Buy |
14
+6
| +75% | +$49.2K | ﹤0.01% | 3967 |
|
|
2016
Q2 | $81K | Buy |
+8
| New | +$67K | ﹤0.01% | 4044 |
|
Other funds holding CLRB
BL
DS
SFA
RCA
WAM
XT
Vanguard Group's CLRB Position: Q4 2025 in Review
Vanguard Group increased its Cellectar Biosciences (CLRB) stake by 37% in Q4 2025, buying an estimated $88.4K and bringing the position to 89,120 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #4064.
Vanguard Group first reported a position in CLRB in Q2 2016 and has held it in 39 quarters since. The position peaked at $4.74M in Q1 2024. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.
- Vanguard Group held 89,120 shares of Cellectar Biosciences worth $263K as of Q4 2025.
- Vanguard Group bought 23,949 Cellectar Biosciences shares in Q4 2025, an estimated $88.4K.
- Cellectar Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4064 holding.
- Vanguard Group first reported a position in Cellectar Biosciences in Q2 2016 and has held it in 39 quarters since.
- Vanguard Group's Cellectar Biosciences position peaked at $4.74M in Q1 2024.
- 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.